Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106684 | 1.00 | PROKR2 (0.75) | PROKR2LMNAPOLBRECQLKDM4E | |
| SCHEMBL565393 | 0.98 | PROKR2 (0.78) | PROKR2LMNAPOLBRECQLKDM4E | |
| SCHEMBL10106681 | 0.98 | PROKR2 (0.78) | PROKR2LMNAPOLBRECQLKDM4E | |
| SCHEMBL565368 | 0.94 | PROKR2 (0.78) | PROKR2LMNAPOLBRECQLKDM4E | |
| SCHEMBL10107343 | 0.94 | PROKR2 (0.78) | PROKR2LMNAPOLBRECQLKDM4E | |
| SCHEMBL564405 | 0.92 | PROKR2 (0.78) | PROKR2POLBKDM4EPDCD1CD274 | |
| SCHEMBL10106703 | 0.92 | PROKR2 (0.78) | PROKR2POLBKDM4EPDCD1CD274 | |
| SCHEMBL10106686 | 0.90 | PROKR2 (0.74) | PROKR2RECQLKDM4EPDCD1CD274 | |
| SCHEMBL565391 | 0.90 | PROKR2 (0.74) | PROKR2RECQLKDM4EPDCD1CD274 | |
| SCHEMBL564281 | 0.90 | PROKR2 (0.76) | PROKR2POLBKDM4EPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | PROKR2, PROKR1, GIPR | PROKR2 1/4885LMNA 704/4885POLB 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.